---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-094622"
form_type: "8-K"
ticker: "ATNM"
cik: "0001388320"
company_name: "Actinium Pharmaceuticals, Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:15:39.427205+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Actinium appoints June Almenoff, M.D., Ph.D. to Board of Directors

## Summary
- Dr. Almenoff brings over 25 years of biopharma leadership; previously President and CMO of Furiex (acquired by Actavis/AbbVie for $1.2B).
- She will serve on the Nominating and Corporate Governance Committee; term as Class III director expires at 2025 annual meeting.
- Granted options for 50,000 shares at $1.71, vesting 28% at 12 months then 2% monthly thereafter.
- Appointment effective November 1, 2024; experienced in translational medicine, clinical development, and regulatory submissions.

## SEC filing metadata
- accession: 0001213900-24-094622
- form_type: 8-K
- ticker: ATNM
- cik: 0001388320
- company_name: Actinium Pharmaceuticals, Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1388320/000121390024094622/0001213900-24-094622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1388320/000121390024094622/ea022011301-8k_actinium.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-094622
- JSON: https://secwatch.observer/filing/0001213900-24-094622.json
- Plain text: https://secwatch.observer/filing/0001213900-24-094622.txt

## Key facts
- Executive change
  June Almenoff was appointed as Director at Actinium Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: On November 1, 2024, June Almenoff, M.D., Ph.D., was appointed as a director of Actinium Pharmaceuticals, Inc. (the “Company”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1388320/000121390024094622/0001213900-24-094622-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.